Predictors of SIV recrudescence following antiretroviral treatment interruption

  1. Mykola Pinkevych
  2. Christine M Fennessey
  3. Deborah Cromer
  4. Carolyn Reid
  5. Charles M Trubey
  6. Jeffrey D Lifson
  7. Brandon F Keele  Is a corresponding author
  8. Miles P Davenport  Is a corresponding author
  1. University of New South Wales, Australia
  2. Frederick National Laboratory for Cancer Research, United States

Abstract

There is currently a need for proxy measures of the HIV rebound competent reservoir (RCR) that can predict viral rebound after combined antiretroviral treatment (cART) interruption. In this study, macaques infected with a barcoded SIVmac239 virus received cART beginning between 4- and 27-days post-infection, leading to the establishment of different levels of viral dissemination and persistence. Later treatment initiation led to higher SIV DNA levels maintained during treatment, which was significantly associated with an increased frequency of SIV reactivation and production of progeny capable of causing rebound viremia following treatment interruption. However, a 100-fold increase in SIV DNA in PBMCs was associated with only a 2-fold increase in the frequency of reactivation. These data suggest that the RCR can be established soon after infection, and that a large fraction of persistent viral DNA that accumulates after this time makes relatively little contribution to viral rebound.

Data availability

Source data files have been provided for Figures.

The following previously published data sets were used

Article and author information

Author details

  1. Mykola Pinkevych

    Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  2. Christine M Fennessey

    AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Deborah Cromer

    Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  4. Carolyn Reid

    AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Charles M Trubey

    AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jeffrey D Lifson

    AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Brandon F Keele

    AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    For correspondence
    keelebf@mail.nih.gov
    Competing interests
    The authors declare that no competing interests exist.
  8. Miles P Davenport

    Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia
    For correspondence
    M.Davenport@unsw.edu.au
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4751-1831

Funding

National Institutes of Health (HHSN261200800001E)

  • Christine M Fennessey
  • Carolyn Reid
  • Charles M Trubey
  • Jeffrey D Lifson
  • Brandon F Keele

National Health and Medical Research Council (1052979)

  • Mykola Pinkevych
  • Deborah Cromer
  • Miles P Davenport

National Health and Medical Research Council (1149990)

  • Mykola Pinkevych
  • Deborah Cromer
  • Miles P Davenport

National Health and Medical Research Council (1080001)

  • Miles P Davenport

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animals were cared for in accordance with the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) standards in an AAALAC-accredited facility and all procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee of the National Cancer Institute (Assurance #A4149-01). Animal care was provided in accordance with the procedures outlined in the "Guide for Care and Use of Laboratory Animals". Reference numbers associated with the ethical approval are AVP047 and AVP058.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,147
    views
  • 171
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mykola Pinkevych
  2. Christine M Fennessey
  3. Deborah Cromer
  4. Carolyn Reid
  5. Charles M Trubey
  6. Jeffrey D Lifson
  7. Brandon F Keele
  8. Miles P Davenport
(2019)
Predictors of SIV recrudescence following antiretroviral treatment interruption
eLife 8:e49022.
https://doi.org/10.7554/eLife.49022

Share this article

https://doi.org/10.7554/eLife.49022

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Axelle Amen, Randy Yoo ... Matthijs M Jore
    Research Article

    Circulating sexual stages of Plasmodium falciparum (Pf) can be transmitted from humans to mosquitoes, thereby furthering the spread of malaria in the population. It is well established that antibodies can efficiently block parasite transmission. In search for naturally acquired antibodies targets on sexual stages, we established an efficient method for target-agnostic single B cell activation followed by high-throughput selection of human monoclonal antibodies (mAbs) reactive to sexual stages of Pf in the form of gametes and gametocyte extracts. We isolated mAbs reactive against a range of Pf proteins including well-established targets Pfs48/45 and Pfs230. One mAb, B1E11K, was cross-reactive to various proteins containing glutamate-rich repetitive elements expressed at different stages of the parasite life cycle. A crystal structure of two B1E11K Fab domains in complex with its main antigen, RESA, expressed on asexual blood stages, showed binding of B1E11K to a repeating epitope motif in a head-to-head conformation engaging in affinity-matured homotypic interactions. Thus, this mode of recognition of Pf proteins, previously described only for Pf circumsporozoite protein (PfCSP), extends to other repeats expressed across various stages. The findings augment our understanding of immune-pathogen interactions to repeating elements of the Plasmodium parasite proteome and underscore the potential of the novel mAb identification method used to provide new insights into the natural humoral immune response against Pf.

    1. Microbiology and Infectious Disease
    Nicolas Flaugnatti, Loriane Bader ... Melanie Blokesch
    Research Article Updated

    The type VI secretion system (T6SS) is a sophisticated, contact-dependent nanomachine involved in interbacterial competition. To function effectively, the T6SS must penetrate the membranes of both attacker and target bacteria. Structures associated with the cell envelope, like polysaccharides chains, can therefore introduce spatial separation and steric hindrance, potentially affecting the efficacy of the T6SS. In this study, we examined how the capsular polysaccharide (CPS) of Acinetobacter baumannii affects T6SS’s antibacterial function. Our findings show that the CPS confers resistance against T6SS-mediated assaults from rival bacteria. Notably, under typical growth conditions, the presence of the surface-bound capsule also reduces the efficacy of the bacterium’s own T6SS. This T6SS impairment is further enhanced when CPS is overproduced due to genetic modifications or antibiotic treatment. Furthermore, we demonstrate that the bacterium adjusts the level of the T6SS inner tube protein Hcp according to its secretion capacity, by initiating a degradation process involving the ClpXP protease. Collectively, our findings contribute to a better understanding of the dynamic relationship between T6SS and CPS and how they respond swiftly to environmental challenges.